Outcomes Among Non-ST-segment Elevation Acute Coronary Syndromes Patients with No Angiographically Obstructive Coronary Artery Disease: Observations from 37,101 Patients

Overview

Journal Eur Heart J Acute Cardiovasc Care

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2014 Feb 25

PMID 24562802

Citations 26

Authors

Gaetano M De Ferrari

Keith A A Fox

Jennifer A White

Robert P Giugliano

Pierluigi Tricoci

Harmony R Reynolds

Judith S Hochman

C Michael Gibson

Pierre Theroux

Robert A Harrington

Frans Van de Werf

Harvey D White

Robert M Califf

L Kristin Newby

Affiliations

Soon will be listed here.

Abstract

Aims: Limited data exist concerning outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) with no angiographically obstructive coronary artery disease (non-obstructive CAD). We assessed the frequency of clinical outcomes among patients with non-obstructive CAD compared with obstructive CAD.

Methods And Results: We pooled data from eight NSTE ACS randomized clinical trials from 1994 to 2008, including 37,101 patients who underwent coronary angiography. The primary outcome was 30-day death or myocardial infarction (MI). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for 30-day death or MI for non-obstructive versus obstructive CAD were generated for each trial. Summary ORs (95% CIs) across trials were generated using random effects models. Overall, 3550 patients (9.6%) had non-obstructive CAD. They were younger, more were female, and fewer had diabetes mellitus, previous MI or prior percutaneous coronary intervention than patients with obstructive CAD. Thirty-day death or MI was less frequent among patients with non-obstructive CAD (2.2%) versus obstructive CAD (13.3%) (OR(adj) 0.15; 95% CI, 0.11-0.20); 30-day death or spontaneous MI and six-month mortality were also less frequent among patients with non-obstructive CAD (OR(adj) 0.19 (0.14-0.25) and 0.37 (0.28-0.49), respectively).

Conclusion: Among patients with NSTE ACS, one in 10 had non-obstructive CAD. Death or MI occurred in 2.2% of these patients by 30 days. Compared with patients with obstructive CAD, the rate of major cardiac events was lower in patients with non-obstructive CAD but was not negligible, prompting the need to better understand management strategies for this group.

Citing Articles

Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link?.

Stangret A, Sadowski K, Jablonski K, Kochman J, Opolski G, Grabowski M Int J Mol Sci. 2024; 25(7).

PMID: 38612695 PMC: 11012077. DOI: 10.3390/ijms25073885.

Comparison between myocardial infarction with non-obstructive coronaries (MINOCA) and myocardial infarct patients with coronary artery disease (MI-CAD): A single-center retrospective cohort study.

Andishmand A, Emami Meybodi M, Namayandeh S, Mohammadi H, Andishmand M, Zarbakhsh M Caspian J Intern Med. 2024; 15(1):109-114.

PMID: 38463910 PMC: 10921117. DOI: 10.22088/cjim.15.1.12.

Value of a short non-contrast CMR protocol in MINOCA.

Gatti M, Palmisano A, Gerboni M, Cau R, Pintus A, Porcu M Eur Radiol. 2023; 34(2):994-1002.

PMID: 37581660 PMC: 10853081. DOI: 10.1007/s00330-023-10096-2.

Sex differences in treatment and outcomes amongst myocardial infarction patients presenting with and without obstructive coronary arteries: a prospective multicentre study.

Lawless M, Appelman Y, Beltrame J, Navarese E, Ratcovich H, Wilkinson C Eur Heart J Open. 2023; 3(2):oead033.

PMID: 37090058 PMC: 10114528. DOI: 10.1093/ehjopen/oead033.

Traditional chinese medicine in coronary microvascular disease.

Yang Z, Lin S, Liu Y, Ren Q, Ge Z, Wang C Front Pharmacol. 2022; 13:929159.

PMID: 36003524 PMC: 9393228. DOI: 10.3389/fphar.2022.929159.

References

. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335(11):775-82. DOI: 10.1056/NEJM199609123351103. View

Morrow D, Antman E, Charlesworth A, Cairns R, Murphy S, de Lemos J . TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000; 102(17):2031-7. DOI: 10.1161/01.cir.102.17.2031. View

Reynolds H, Srichai M, Iqbal S, Slater J, Mancini G, Feit F . Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011; 124(13):1414-25. PMC: 3619391. DOI: 10.1161/CIRCULATIONAHA.111.026542. View

Gulati M, Cooper-DeHoff R, McClure C, Johnson B, Shaw L, Handberg E . Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009; 169(9):843-50. PMC: 2782882. DOI: 10.1001/archinternmed.2009.50. View

Ferguson J, Califf R, Antman E, Cohen M, Grines C, Goodman S . Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004; 292(1):45-54. DOI: 10.1001/jama.292.1.45. View

Boersma E, Pieper K, Steyerberg E, Wilcox R, Chang W, Lee K . Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000; 101(22):2557-67. DOI: 10.1161/01.cir.101.22.2557. View

Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey Jr D . 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart.... Circulation. 2011; 123(18):e426-579. DOI: 10.1161/CIR.0b013e318212bb8b. View

Merz C, Shaw L, Reis S, Bittner V, Kelsey S, Olson M . Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and.... J Am Coll Cardiol. 2006; 47(3 Suppl):S21-9. DOI: 10.1016/j.jacc.2004.12.084. View

Bugiardini R, Manfrini O, De Ferrari G . Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med. 2006; 166(13):1391-5. DOI: 10.1001/archinte.166.13.1391. View

10.

Diver D, Bier J, Ferreira P, Sharaf B, McCabe C, Thompson B . Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol. 1994; 74(6):531-7. DOI: 10.1016/0002-9149(94)90739-0. View

11.

Eagle K, Lim M, Dabbous O, Pieper K, Goldberg R, Van de Werf F . A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291(22):2727-33. DOI: 10.1001/jama.291.22.2727. View

12.

Mukherjee D, Mahaffey K, Moliterno D, Harrington R, Yadav J, Pieper K . Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002; 144(6):995-1002. DOI: 10.1067/mhj.2002.126118. View

13.

Gehrie E, Reynolds H, Chen A, Neelon B, Roe M, Gibler W . Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with.... Am Heart J. 2009; 158(4):688-94. DOI: 10.1016/j.ahj.2009.08.004. View

14.

Roe M, Harrington R, Prosper D, Pieper K, Bhatt D, Lincoff A . Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT).... Circulation. 2000; 102(10):1101-6. DOI: 10.1161/01.cir.102.10.1101. View

15.

. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events.... Circulation. 1998; 97(24):2386-95. DOI: 10.1161/01.cir.97.24.2386. View

16.

. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998; 338(21):1498-505. DOI: 10.1056/NEJM199805213382103. View

17.

Hochman J, Tamis J, Thompson T, Weaver W, White H, Van de Werf F . Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999; 341(4):226-32. DOI: 10.1056/NEJM199907223410402. View

18.

Topol E, Nissen S . Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation. 1995; 92(8):2333-42. DOI: 10.1161/01.cir.92.8.2333. View

19.

Stone G, Maehara A, Lansky A, De Bruyne B, Cristea E, Mintz G . A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011; 364(3):226-35. DOI: 10.1056/NEJMoa1002358. View

20.

De Ferrari G, Leonardi S, Baduena L, Chieffo E, Lesce A, Repetto A . Patients with acute coronary syndrome and nonobstructive coronary artery disease in the real world are markedly undertreated. J Cardiovasc Med (Hagerstown). 2011; 12(10):700-8. DOI: 10.2459/JCM.0b013e328348e575. View